Artelo Biosciences
NASDAQ: ARTLSolana Beach, US · Nevada corporation
Find your way into Artelo Biosciences
430 people in our graph share verified history with the Artelo Biosciences team — schools, employers, funds. One of them is your warm intro.
Richard Leeunlockedknows Peter O'Brien · together at HSBC (overlapped)
knows the team · via HSBC
×2knows the team · via Purdue University
×4knows the team · via University of Phoenix
×4knows the team · via California State University, Northridge
Artelo Biosciences develops therapeutic treatments by modifying lipid signaling pathways to treat cancer and other serious conditions at the clinical stage.
Founders & leadership
GD
Gregory D. GorgasinPresident & CEOGregory D. Gorgas holds an MBA from University of Phoenix and a BA in Economics from California State University, Northridge. He has worked in pharmaceutical and biotech commercialization roles spanning three decades, including positions at Upjohn, Chiron, and IDEC (where he led sales for Rituxan's launch), prior to co-founding Theragence and serving as Senior Vice President of Commercial at Mast Therapeutics before becoming President and CEO of Artelo Biosciences in 2017.
PO
Peter O'BrieninSenior Vice President Europe / Nasdaq2017–2021Co-founder of Ventry Technologies, an energy efficiency company; previously worked on HVO fuel deployment in Ireland and energy infrastructure projects across Europe, the Middle East, and Africa.
Board
CM
Connie MatsuiBoard director
SK
Steven KellyBoard director
DB
GR
Gregory R. ReyesBoard director
TA
Tamara A. FavoritoBoard director
RM
R. Martin EmanueleBoard director
Reported raises · per SEC filings
Form D private placements$33.4M disclosed across 14 of 15 rounds · 2017–2026
▶$11MraisedApr 2026 · 2 investors · BiotechnologyRule 506(b)
▶$11MraisedApr 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $11M
- Sales commissions
- $880K
- Proceeds to insiders
- $575.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$113KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$113KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $113K
- Amount sold
- $113K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$237.3KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$237.3KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Mark SpringExecutive Officer, Director
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $237.3K
- Amount sold
- $237.3K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$315KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$315KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory D. GorgasExecutive Officer, Director
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Steven KellyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Offering amount
- $315K
- Amount sold
- $315K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$500KraisedFeb 2026 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedFeb 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Tamara A. FavoritoDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Offering amount
- $50.5M
- Amount sold
- $500K
- First sale
- Jan 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.7MraisedNov 2025 · 14 investors · BiotechnologyRule 506(b)
▶$3.7MraisedNov 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Steven KellyDirector
- Tamara A. FavoritoDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$9.5MraisedAug 2025 · 18 investors · BiotechnologyRule 506(b)
▶$9.5MraisedAug 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory R. ReyesDirector
- Connie MatsuiDirector
- Gregory D. GorgasExecutive Officer, Director
- Steven KellyDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Douglas BlayneyDirector
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Aug 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.4MraisedJul 2025 · 8 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJul 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Connie MatsuiDirector
- Steven KellyDirector
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Jun 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$10.3Mvaluation at IPOOct 2020 · $0.75/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 7
by search overlap
Seeking Alpha23 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood20 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Interactive Strength Acquires Ergatta20 shared keywordsFidelity offers an online brokerage platform for retail investors to trade US stocks, ETFs, options, mutual funds, bonds, CDs, and crypto ETPs, with $0 commission on online US stock and ETF trades. It provides trading across web, desktop, and mobile alongside research tools, professional coaching, and advisory services.
StockTwits19 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St18 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Perplexity17 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Artelo Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies | The Manila Timesmanilatimes.net · Aug 2026
Artelo Biosciences posts $5.4M loss but cuts debt | ARTL Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Artelo Biosciences do?
- Artelo Biosciences develops therapeutic treatments by modifying lipid signaling pathways to treat cancer and other serious conditions at the clinical stage.
- How much funding has Artelo Biosciences raised?
- Artelo Biosciences has disclosed $33.4M raised across 14 of its 15 known rounds.
- Where is Artelo Biosciences headquartered?
- Artelo Biosciences is headquartered in Solana Beach, US.